BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35691176)

  • 1. Discovery of highly potent and selective CRBN-recruiting EGFR
    Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
    Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.
    Li Q; Guo Q; Wang S; Wan S; Li Z; Zhang J; Wu X
    Eur J Med Chem; 2022 Aug; 238():114455. PubMed ID: 35594654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD9291 overcomes T790┬áM-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
    Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent small molecule PROTACs targeting mutant EGFR.
    Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
    Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
    Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFR
    Xu J; Zhu GY; Cao D; Pan H; Li YW
    Biomed Pharmacother; 2019 Jul; 115():108860. PubMed ID: 31055235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).
    Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC.
    Chen L; Zhang Y; Tian L; Wang C; Deng T; Zheng X; Wang T; Li Z; Tang Z; Meng Q; Sun H; Li L; Ma X; Xu Y
    Eur J Med Chem; 2021 Nov; 223():113626. PubMed ID: 34218082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of novel dihydroquinoxalinone derivatives as EGFR
    Cao Y; Lu X; Fu L; Shi T; Zhang C; Zeng L; Zhang J; Shao J; Xi J; Pan Z; Liu S; Zhu H
    Bioorg Chem; 2023 Jun; 135():106494. PubMed ID: 37011522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.
    Zhao HY; Wang HP; Mao YZ; Zhang H; Xin M; Xi XX; Lei H; Mao S; Li DH; Zhang SQ
    J Med Chem; 2022 Mar; 65(6):4709-4726. PubMed ID: 35254067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer.
    Pei J; Wang G; Wang A; Wu C; Pan X; Shuai W; Bu F; Zhu Y; Wang Y; Ouyang L; Li W
    J Med Chem; 2023 Apr; 66(8):5719-5752. PubMed ID: 37042119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel 4-arylamino-quinazoline derivatives as EGFR
    Gan W; Wang C; Pan Q; Li Y; Guo Y; Fan D; Peng Y; Rao Z; Xu S; Zheng P; Zhu W
    Bioorg Chem; 2022 Oct; 127():105994. PubMed ID: 35792314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of 2-arylamino-4-(piperidin-4-yloxy)pyrimidines as potent EGFR
    Tian L; Li X; Lv Z; Yang Y; Wang L; Xu D; Ma X; Xu Y
    Bioorg Med Chem; 2022 Nov; 74():117052. PubMed ID: 36288657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of selective degraders of EGFR
    Zhang X; Xu F; Tong L; Zhang T; Xie H; Lu X; Ren X; Ding K
    Eur J Med Chem; 2020 Apr; 192():112199. PubMed ID: 32171162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of hydroxamic acid-substituted 2,4-diaryl aminopyrimidines as potent EGFRT790M/L858R inhibitors for the treatment of NSCLC.
    Chen L; Zhang Y; Wang C; Tang Z; Meng Q; Sun H; Qi Y; Ma X; Li L; Li Y; Xu Y
    Bioorg Chem; 2021 Sep; 114():105045. PubMed ID: 34161879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors.
    Ding S; Gao Z; Hu Z; Qi R; Zheng X; Dong X; Zhang M; Shen J; Long T; Zhu Y; Tian L; Song W; Liu R; Li Y; Sun J; Duan W; Liu J; Chen Y
    Eur J Med Chem; 2022 Aug; 238():114492. PubMed ID: 35696862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.